Millennium, a division of the Takeda Oncology Company in Japan, is a leading biopharmaceutical company based in Cambridge, Massachuesets. Millenium markets VELCADE, a proteasome inhibitor which is primarily used in multiple myeloma patients.
We can thank Biosciencetechnology.com for this report about continuing genetic research which may help treat some non-Hodgkin’s lymphoma patients:
We found this info on Media-Newswire.com. Good news for lymphoma patients?
Chicago’s WLS TV’s Website posted this short article about Hepatitis B raising the risk to lymphoma patients:
Cancer Research UK recently said that people diagnosed with non-Hodgkin’s lymphoma, bowel, breast and ovarian cancer – cancers that are notoriously difficult to treat and sometimes end in death – are now surviving in numbers that double previous figures.
Here is an article we found posted on a local TV Website, about a high school girl with a difficult to treat form of non-Hodgkin’s lymphoma:
Hey–check-out this article about Microsoft co-founder and cancer survivor Paul Allen:
Microsoft co-founder pledges fortune to philanthropy
Thu Jul 15, 2010
Microsoft Corp (MSFT.O) co-founder Paul Allen, who has been treated for non-Hodgkin’s lymphoma, said on Thursday he is committing most of his estimated $13.5 billion fortune to philanthropy after his death.
Here is a short article from Better Health Research about the benefits of vitamin K for people at-risk for non-Hodgkins lymphoma:
FDA Approves Lymphoma Drug Developed at Memorial Sloan-Kettering
I got so busy I forgot to post this Vitamin D news from ASH:
Last evening I wrote about an e-mail I had just received from Manisha Pai with Millennium about break-through results for lymphoma patients, using a multiple myeloma drug, Velcade. She has now cleared the release of the info. Here is a copy of her press release draft. Official release will be later today:
Manisha Pai, one of Millennium’s top PR execs, just e-mailed me the rough draft for a press release she was working on, from her flight back to Boston, a few moments ago. Here is the proposed header/lead/headline:
The real excitement here starts at 2:30. That is when the major newsworthy studies, as determined by the ASH board, begin to be presented. Until then, all is speculation and rumor. They call in an information embargo. Drug company reps and researchers aren’t allowed to discuss details of their clinical studies until they are presented this afternoon, evening, all day Monday and ending Tuesday. Studies deemed less significant are relegated to a large room of “poster presentations.” I spent a lot of time there this morning and found it fascinating. You walk into a large exhibit hall (about the size of four football fields) and before you stand row upon row of display boards. Pinned to these boards are 4′ x 6′ posters. Each poster is a color reproduction of a scientific journal study, just like you would find on line. Studies are grouped by topic. For example, clinical data on non-Hodgkins lymphoma would be grouped in one section in one row. It’s sort of cool yet silly all at the same time… Instead of reading grouped studies on computer, you are walking up and down between these rows of posters. Most don’t even have handouts available. Some people take notes, some take pictures. All seem to be in English. The lead researchers of the studies are scheduled to be present in two hour blocks once or twice during the conference to answer questions. The draw seems to be the immediacy of it all–these studies won’t be published and available on-line until after the conference concludes next week.
One of the characters on the ABC Sunday night drama, “Brothers and Sisters,” was told tonight she has “Stage III lymphoma,” and the recommended treatment on the program was is R-CHOP. I know it is only a TV show, but Pattie and I are always intrigued by how Hollywood portrays how cancer effects friends and families. And call us unrealistic or difficult, but we also like accuracy in my cancer dramas. As movies and programs go, this storyline isn’t so bad. Working our way backward, we can assume the character, Kitty, has Stage III non-Hodgkins lymphoma. Here is what About.Com says about R-CHOP:
Found this article this morning on a site called RobertsReview.Com. There must be a catch. I can’t believe such treatments exist and aren’t being used or embraced by oncologists for selfish reasons like article claims in the last paragraph. No study sited or author listed so read it carefully and with a skeptical eye:
Sorry, meat eaters! Check out this article in Reuters:
Hon-Hodgkin’s Lymphomas are the second leading cause of cancer deaths in patients ages fifteen to thirty-four and the third leading cause of cancer deaths in patients ages thirty-one to fifty-four. An estimated 63,190 new cases of Non-Hodgkin’s Lymphoma were diagnosed in the United States during 2007, according to the book Everyone’s Guide to Cancer Therapy. This is a difficult type of cancer to cure. But depending on the specific type of Non-Hodgkin’s Lymphoma and how early the cancer is identified, patients often can live many years with good treatment and follow-up care. For more information about Non-Hodgkin’s Lymphoma, click on the Leukemia and Lymphoma Society link on the right side of the page.
Since it’s mother’s day, I felt it was appropriate to post about a topic important to women. EverydayHealth.Com featured an article yesterday listing the five most common types of cancer among women. I found it interesting/helpful because it also gave survival data and percentages of women affected. The five most common cancers in women are:
Here is a list of cancers that respond best to stem cell transplants according to the Fifth Addition of Everyone’s Guide to Cancer Therapy:
It took me eight days to produce nine million cells during my stem cell harvest. That is after five days of multiple injections to get my cells ready to go. Several drugs like Plerixafor have been approved recently. Good news for patients that already have enough to worry about!